Essentials for Clinicians: Gynaecological Tumours - Editors and Contributors

Editors

  • Andreas du Bois,Arbeitsgemeinschaft Gynaekologische Onkologie Study Group Kliniken Essen-Mitte, Department of Gynaecology and Gynaecologic Oncology, Essen, Germany
  • Marcia Hall, Mount Vernon Cancer Centre Northwood, UK
  • Christina C Fotopoulou, Ovarian Cancer Action Research Centre Department of Surgery and Cancer Imperial College London, UK 

Series editor: Michele Ghielmini, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Contributors

Chapter 1 - Histopathology of gynaecological cancers 

  • GD Aletti - Department of Gynaecologic Oncology, European Institute of Oncology, Milan, Italy
  • S Carinelli - Department of Pathology, European Institute of Oncology, Milan, Italy 

Chapter 2 - Staging and surgical treatment of ovarian cancer 

  • S Mahner - Department of Gynecology and Obstetrics, University of Munich, Munich, Germany 
  • L Woelber - University Medical Center Hamburg-Eppendorf, Department of Gynecology, Hamburg, Germany 

Chapter 3 - Systemic treatment of ovarian cancer 

  • D Krell - Mount Vernon Cancer Centre, Northwood, UK 
  • M Hall - Mount Vernon Cancer Centre, Northwood, UK

Chapter 4 - Staging and surgical treatment of endometrial cancer 

  • MJ Halaska - Gynecologic Oncology Center, Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University, Prague, Czech Republic 
  • L Rob - Gynecologic Oncology Center, Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University, Prague, Czech Republic 

Chapter 5 - Non-surgical treatment of endometrial cancer 

  • M Mirza - Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark 

Chapter 6 - Staging and surgical treatment of cervical cancer 

  • D Cibula - Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Charles University in Prague and General University Hospital in Prague, Czech Republic 

Chapter 7 - Non-surgical treatment of cervical cancer 

  • S Marnitz - Department of Radiation Oncology, Charité University Medicine, Berlin, Germany 

CC Fotopoulou - Department of Gynecological Oncology, Imperial College London, London, UK 

Chapter 8 - Epidemiology and risk factors for ovarian, uterine and cervical cancers 

  • A Gonzalez Martin - MD Anderson Cancer Center, Madrid, Spain 

Chapter 9 - Diagnosis and treatment of vulvar cancer 

  • L Rob - Gynecologic Oncology Center, Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University, Prague, Czech Republic 
  • P Skapa - Department of Pathology and Molecular Biology, Second Medical Faculty, Charles University, Prague, Czech Republic 

Chapter 10 - Rare gynaecological cancers 

  • I Ray-Coquard - Medical Oncology, Centre Léon Bérard, Lyon, France 
  • H Vanacker - Medical Oncology, Centre Léon Bérard, Lyon, France 

Chapter 11 - Hereditary ovarian and uterine cancer syndromes 

  • C Marth - Department of Obstetrics and Gynecology, Medical University, Innsbruck, Austria 

Chapter 12 - New drugs and novel treatment strategies for gynaecological cancers 

  • M Zweifel - Department of Medical Oncology, University Hospital Bern, Switzerland 
  • C Sessa - Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland 

Declarations of interest

  • GD Aletti: No conflicts of interest.
  • S Carinelli: No conflicts of interest.
  • D Cibula: No conflicts of interest.
  • CC Fotopoulou: No conflicts of interest.
  • A Gonzalez Martin: No conflicts of interest.
  • MJ Halaska: No conflicts of interest.
  • M Hall: Advisory Boards for GlaxoSmithKline, Roche, AstraZeneca, Merck.
  • D Krell: No conflicts of interest.
  • S Mahner: No conflicts of interest.
  • S Marnitz: No conflicts of interest. 
  • C Marth: No conflicts of interest.
  • M Mirza: No conflicts of interest.
  • I Ray-Coquard: No conflicts of interest.
  • L Rob: No conflicts of interest.
  • C Sessa: No conflicts of interest.
  • P Skapa: No conflicts of interest.
  • H Vanacker: No conflicts of interest.
  • L Woelber: No conflicts of interest.
  • M Zweifel: Advisory role for Roche. 

« Previous Page

Last update: 27 June 2017